Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer
Subjects
More information
Scope and Contents
Contents
Leucine-rich alpha-2 glycoprotein (LRG) is a newly studied biomarker for inflammatory diseases. This study aimed to investigate whether LRG can be used for evaluating transmural activity in patients with Crohn's disease (CD).
We performed magnetic resonance enterography (MRE) in 227 consecutive patients with CD from June 2020 to August 2021. We...
Alternative Titles
Full title
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2758355027
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2758355027
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.14309/ajg.0000000000002127
